高级搜索
甲状腺癌中CCR7和D2-40的表达及其与淋巴结转移的关系[J]. 肿瘤防治研究, 2014, 41(05): 418-422. DOI: 10.3971/j.issn.1000-8578.2014.05.016
引用本文: 甲状腺癌中CCR7和D2-40的表达及其与淋巴结转移的关系[J]. 肿瘤防治研究, 2014, 41(05): 418-422. DOI: 10.3971/j.issn.1000-8578.2014.05.016
Correlation between Expression of CCR7, D2-40 and Lymphatic Metastases in Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 418-422. DOI: 10.3971/j.issn.1000-8578.2014.05.016
Citation: Correlation between Expression of CCR7, D2-40 and Lymphatic Metastases in Thyroid Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 418-422. DOI: 10.3971/j.issn.1000-8578.2014.05.016

甲状腺癌中CCR7和D2-40的表达及其与淋巴结转移的关系

Correlation between Expression of CCR7, D2-40 and Lymphatic Metastases in Thyroid Carcinoma

  • 摘要: 目的 研究趋化因子受体7(CCR7)及D2-40在甲状腺癌组织中的表达及其与淋巴结转移的关系。方法 应用MAX Vision免疫组织化学法研究二者在甲状腺癌和正常甲状腺组织中的表达情况,并以淋巴管内皮标记物D2-40计算微淋巴管密度 (lymphatic microvessel density, MLVD)。结果 CCR7在87例甲状腺癌和正常甲状腺组织中阳性率分别为66.7%和15%;乳头状癌、髓样癌、滤泡癌、未分化癌CCR7阳性率分别为75.0%、70.0%、73.0%、25.0%,淋巴结阳性组(40⁄49)与淋巴结阴性组(18⁄38)CCR7阳性率分别为81.6%、47.4%(P<0.05)。D2-40标记的MLVD计数在甲状腺癌和正常甲状腺组织中分别为5.72±2.89??2.60±1.14,甲状腺乳头状癌、髓样癌、滤泡癌、未分化癌中分别为7.55±2.29、6.60±1.75、4.27±1.10、1.00±0.34。甲状腺癌中淋巴结阳性组与淋巴结阴性组D2-40标记的MLVD计数分别为9.39±4.24、3.24±1.67(P<0.05)。CCR7阳性组MLVD(9.37±2.25)高于阴性组(5.51±2.47),差异有统计学意义 (P<0.05)。D2-40标记的MLVD与CCR7 表达呈正相关(rs=0.645,P<0.001)。CCR7、D2-40标记的MLVD 与淋巴结转移呈正相关,甲状腺癌中淋巴结转移阳性组CCR7、D2-40标记的MLVD 高于淋巴结转移阴性组。结论 肿瘤细胞高表达CCR7,D2-40能标记肿瘤淋巴管,联合监测CCR7与D2-40有望成为判断淋巴转移更为有效的指标。

     

    Abstract: Objective To investigate the relationship between expression of CCR7, D2-40 and lymph node metastasis in thyroid carcinoma tissues. Methods The expression of CCR7 and D2-40 were measured in 87 cases of thyroid carcinoma tissues and 20 cases of normal thyroid tissues by MAX Vision immunohistochemical staining technique. The expression of lymphatic endothelial markers D2-40 was applied to calculate lymphatic microvessel density(MLVD). Results CCR7 positive rate was 66.7% in the 87 cases of thyroid carcinoma tissues and CCR7 positive rate was 15% in the 20 cases of normal thyroid tissues; CCR7 positive rates were counted up to 75.0%, 70.0%, 73.0% and 25.0% in PTC, MTC, FTC and UTC, retrospectively; CCR7 positive rate was 81.6%(40⁄49)in lymph node metastasis positive patients and 47.4% (18⁄38) in lymph node metastasis negative patients(P<0.05). MLVD counts in thyroid carcinoma tissues and normal tissues were (5.72±2.89) and (2.60±1.14); MLVD counts in PTC, MTC, FTC and UTC were (7.55±2.29), (6.60±1.75), (4.27±1.10) and (1.00±0.34), respectively; MLVD counts in lymph node metastasis positive patients was obviously higher than that in lymph node metastasis negative patients (9.39±4.24), (3.24±1.67), P<0.05. MLVD expression was positively correlated with CCR7 expression ( rs=0.645,P<0.001). CCR7 and MLVD were positively related with lymphatic metastasis. The positive rates of CCR7 and MLVD in lymph node-positive group were higher than those in lymph node-negative group. Conclusion D2-40 staining only presents in lymphatic endothelial cells. The united detection of CCR7 along with D2-40 is expected to be the inchoate and more effective signal to judgment lymph node metastases.

     

/

返回文章
返回